FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (in 2026)

FDA decision on bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) in 2026 If the FDA's decision on bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) is an investigational, once-daily, single-t